Chronic Kidney Disease
Conditions
Keywords
Kidney, Renal
Brief summary
The purpose of this study is to investigate the safety and tolerability of LY2623091 after multiple oral dosing in healthy men and women of non-childbearing potential. Two cohorts of 16 subjects will participate in 2 dosing periods. Treatment assignment will be double-blind for LY2623091 and placebo (negative control), and open label for eplerenone (positive control).
Interventions
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Are healthy men and women of non-childbearing potential as determined by medical history and physical examination. * Male subjects: Non-vasectomized male subjects must agree to use 2 medically accepted methods of contraception with all sexual partners during the study and for 90 days following the final dosing. * Female subjects: Female subjects must be of non-childbearing potential due to surgical sterilization (hysterectomy, bilateral oophorectomy or tubal ligation) or menopause. They should be a minimum of 12 months without a menstrual period. Peri-menopausal women who are 6 months without a menstrual period. * Have given written informed consent prior to any study-specific procedures. * Are reliable and willing to make themselves available for the duration of the study and are willing to follow site-specific study procedures. * Have a body mass index (BMI) of between 19 and 32.5 kilograms per square meter (kg/m\^2). * Have clinical laboratory test results within the normal reference range for the population or study site, or test results with acceptable deviations that are judged by the Investigator not to be clinically significant. * Have venous access sufficient to allow blood sampling per the protocol. * Have serum potassium levels within the normal range. * Are nonsmokers or smokers of less than or equal to 10 cigarettes per day.
Exclusion criteria
* Are currently enrolled in, or have discontinued, within 60 days inclusive, a clinical trial involving an investigational drug, device or an off-label use of an approved drug, or are concurrently enrolled in any other type of medical research judged to be scientifically or medically incompatible with this study. Subjects who meet any of these criteria may be enrolled in this study but they cannot be dosed until at least 60 days following the last day of the previous investigational trial. * Have previously completed or withdrawn from this study or any other study investigating LY2623091. * Have a history or presence of medical illness including but not limited to any cardiovascular, hepatic, respiratory, hematological, endocrine or neurological disease, or any clinically significant laboratory abnormality that is of a serious medical problem that would preclude study participation. * Have an abnormality in the 12-lead electrocardiogram (ECG), which increases the risks associated with participation in the study. * Are unwilling or unable to comply with the use of an electronic data capture system. * Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV antibodies, hepatitis C and/or positive hepatitis C antibody or hepatitis B and/or positive hepatitis B surface antigen. * Use and/or intend to use any medication for a medical condition that is not compatible with Inclusion Criterion. For medications that may be used in healthy subjects (example given: preventative and/or naturopathic agents, temporary symptom-relieving medications, and so forth) the following constraints must be observed: * No use of vasoactive drugs (example given: diuretics, antihypertensive agents, phosphodiesterase inhibitors, erectile dysfunction medications, nasal decongestants, et cetera) or systemic glucocorticoids within 7 days of first dosing and/or anticipated use during the study. * No use of acetaminophen/paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) within 24 hours of first dosing and/or anticipated use during the study. Aspirin may not be used at doses greater than 100 milligrams per day (mg/day) within 7days of first dosing and/or anticipated use during the study. * No use of herbal or nutritional products within 7 days of first dosing and/or anticipated use during the study. * Have donated blood of more than 50 milliliters (mL) within the last 60 days. * Have an average weekly alcohol intake that exceeds 21 units per week and/or subjects unwilling to stop alcohol within 48 hours of study enrollment and for the duration of the study. * Have an abnormally high blood pressure (supine or standing) defined as diastolic blood pressure greater than 95 millimeters of mercury (mmHg) and /or systolic blood pressure greater than 150 mmHg, confirmed by at least 1 repeat measurement. * Have serum potassium greater than the upper limit of normal. * Regularly use known drugs of abuse or show positive findings for such use on urinary drug screening. * Consumption of natural licorice and/or natural licorice-containing products and/or grapefruit and/or grapefruit juice within 7 days of first dosing and/or anticipated consumption during the study. * Consumption of methylxanthine-containing beverages and/or foods (example: coffee, tea, caffeinated soft drinks, chocolate) within 4 days of first dosing and/or anticipated consumption during the study. * Are unwilling to abstain from salt-substitutes containing potassium for the duration of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Clinically Significant Effects (Adverse Events) | Baseline through 7 days for each treatment period | A summary of serious adverse events and other nonserious adverse events are located in the Reported Adverse Event section. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacodynamics: Serum to Urine Potassium Area Under the Concentration-Time Curve (AUC) Standardized for Urinary Excretion at Day 7 | Day 7: 24 Hour (hr), 48hr and 72hr Postdose | A measure of the renal clearance of the potassium ion (K+). The Least Squares (LS) Mean value was adjusted for pre-challenge renal K+ clearance. |
| Pharmacokinetics of LY2623091: Maximal Concentration (Cmax) at Day 6 | Day 6: Predose,1hr, 2hr, 3hr, 4hr, 8hr and 12 hr Postdose | Cmax estimated for LY2623091. |
| Pharmacokinetics LY2623091: Area Under the Concentration-Time Curve (AUC) at Day 6 | Day 6: Predose,1hr, 2hr, 3hr, 4hr, 8hr and 12 hr Postdose | AUC from time 0, extrapolated to infinity, estimated for LY2623091. |
Countries
Netherlands
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| 1 mg LY2623091 First Then 25 mg LY2623091 1 mg LY2623091 daily by mouth for 7 days, followed by a minimum 7-day washout period before receiving 25 mg LY2623091 daily by mouth for 7 days. | 1 |
| 1 mg LY2623091 First Then Placebo 1 mg LY2623091 daily by mouth for 7 days, followed by a minimum 7-day washout period before receiving placebo daily by mouth for 7 days. | 3 |
| 1 mg LY2623091 First Then 50 mg Eplerenone 1 mg LY2623091 daily by mouth for 7 days, followed by a minimum 7-day washout period before receiving 50 mg eplerenone daily by mouth for 7 days. | 4 |
| 50 mg Eplerenone First Then 25 mg LY2623091 50 mg eplerenone daily by mouth for 7 days, followed by a minimum 7-day washout period before receiving 25 mg LY2623091 daily by mouth for 7 days. | 3 |
| 50 mg Eplerenone First Then Placebo 50 mg eplerenone daily by mouth for 7 days, followed by a minimum 7-day washout period before receiving placebo daily by mouth for 7 days. | 2 |
| Placebo First Then 25 mg LY2623091 Placebo daily by mouth for 7 days, followed by a minimum 7-day washout period before receiving 25 mg LY2623091 daily by mouth for 7 days. | 4 |
| 10 mg LY2623091 First Then 0.3 mg LY2623091 10 mg LY2623091 daily by mouth for 7 days, followed by a minimum 7-day washout period before 0.3 mg LY2623091 daily by mouth for 7 days. | 1 |
| 10 mg LY2623091 First Then Placebo 10 mg LY2623091 daily by mouth for 7 days, followed by a minimum 7-day washout period before receiving placebo daily by mouth for 7 days. | 3 |
| 10 mg LY2623091 First Then 50 mg Eplerenone 10 mg LY2623091 daily by mouth for 7 days, followed by a minimum 7-day washout period before receiving 50 mg eplerenone daily by mouth for 7 days. | 4 |
| 50 mg Eplerenone First Then 0.3 mg LY2623091 50 mg eplerenone daily by mouth for 7 days, followed by a minimum 7-day washout period before receiving 0.3 mg LY2623091 daily by mouth for 7 days. | 3 |
| Placebo Then 0.3 mg LY2623091 Placebo daily by mouth for 7 days, followed by a minimum 7-day washout period before receiving 0.3 mg LY2623091 daily by mouth for 7 days. | 4 |
| Total | 32 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 | FG010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Washout Period of at Least 7 Days | Adverse Event | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Total | 1 mg LY2623091 First Then 25 mg LY2623091 | 1 mg LY2623091 First Then Placebo | 1 mg LY2623091 First Then 50 mg Eplerenone | 50 mg Eplerenone First Then 25 mg LY2623091 | 50 mg Eplerenone First Then Placebo | Placebo First Then 25 mg LY2623091 | 10 mg LY2623091 First Then 0.3 mg LY2623091 | 10 mg LY2623091 First Then Placebo | 10 mg LY2623091 First Then 50 mg Eplerenone | 50 mg Eplerenone First Then 0.3 mg LY2623091 | Placebo Then 0.3 mg LY2623091 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 32 Participants | 1 Participants | 3 Participants | 4 Participants | 3 Participants | 2 Participants | 4 Participants | 1 Participants | 3 Participants | 4 Participants | 3 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 32 Participants | 1 Participants | 3 Participants | 4 Participants | 3 Participants | 2 Participants | 4 Participants | 1 Participants | 3 Participants | 4 Participants | 3 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian | 2 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized White | 30 Participants | 1 Participants | 2 Participants | 4 Participants | 3 Participants | 2 Participants | 4 Participants | 1 Participants | 2 Participants | 4 Participants | 3 Participants | 4 Participants |
| Region of Enrollment Netherlands | 32 Participants | 1 Participants | 3 Participants | 4 Participants | 3 Participants | 2 Participants | 4 Participants | 1 Participants | 3 Participants | 4 Participants | 3 Participants | 4 Participants |
| Sex: Female, Male Female | 3 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 29 Participants | 1 Participants | 2 Participants | 4 Participants | 3 Participants | 2 Participants | 2 Participants | 1 Participants | 3 Participants | 4 Participants | 3 Participants | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 6 / 16 | 2 / 8 | 5 / 8 | 4 / 8 | 6 / 8 | 9 / 15 |
| serious Total, serious adverse events | 0 / 16 | 0 / 8 | 0 / 8 | 0 / 8 | 0 / 8 | 0 / 15 |
Outcome results
Primary
Number of Participants With Clinically Significant Effects (Adverse Events)
A summary of serious adverse events and other nonserious adverse events are located in the Reported Adverse Event section.
Time frame: Baseline through 7 days for each treatment period
Population: All participants who received at least 1 dose of study drug.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Placebo | Number of Participants With Clinically Significant Effects (Adverse Events) | Serious Adverse Events | 0 Participants |
| Placebo | Number of Participants With Clinically Significant Effects (Adverse Events) | Nonserious Adverse Events | 6 Participants |
| 0.3 mg LY2623091 | Number of Participants With Clinically Significant Effects (Adverse Events) | Serious Adverse Events | 0 Participants |
| 0.3 mg LY2623091 | Number of Participants With Clinically Significant Effects (Adverse Events) | Nonserious Adverse Events | 2 Participants |
| 1 mg LY2623091 | Number of Participants With Clinically Significant Effects (Adverse Events) | Serious Adverse Events | 0 Participants |
| 1 mg LY2623091 | Number of Participants With Clinically Significant Effects (Adverse Events) | Nonserious Adverse Events | 5 Participants |
| 10 mg LY2623091 | Number of Participants With Clinically Significant Effects (Adverse Events) | Serious Adverse Events | 0 Participants |
| 10 mg LY2623091 | Number of Participants With Clinically Significant Effects (Adverse Events) | Nonserious Adverse Events | 4 Participants |
| 25 mg LY2623091 | Number of Participants With Clinically Significant Effects (Adverse Events) | Serious Adverse Events | 0 Participants |
| 25 mg LY2623091 | Number of Participants With Clinically Significant Effects (Adverse Events) | Nonserious Adverse Events | 6 Participants |
| 50 mg Eplerenone | Number of Participants With Clinically Significant Effects (Adverse Events) | Serious Adverse Events | 0 Participants |
| 50 mg Eplerenone | Number of Participants With Clinically Significant Effects (Adverse Events) | Nonserious Adverse Events | 9 Participants |
Secondary
Pharmacodynamics: Serum to Urine Potassium Area Under the Concentration-Time Curve (AUC) Standardized for Urinary Excretion at Day 7
A measure of the renal clearance of the potassium ion (K+). The Least Squares (LS) Mean value was adjusted for pre-challenge renal K+ clearance.
Time frame: Day 7: 24 Hour (hr), 48hr and 72hr Postdose
Population: All participants who received at least 1 dose of study drug and for whom the data are considered sufficient and interpretable.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo | Pharmacodynamics: Serum to Urine Potassium Area Under the Concentration-Time Curve (AUC) Standardized for Urinary Excretion at Day 7 | 2.098 liter per hour (L/h) |
| 0.3 mg LY2623091 | Pharmacodynamics: Serum to Urine Potassium Area Under the Concentration-Time Curve (AUC) Standardized for Urinary Excretion at Day 7 | 1.940 liter per hour (L/h) |
| 1 mg LY2623091 | Pharmacodynamics: Serum to Urine Potassium Area Under the Concentration-Time Curve (AUC) Standardized for Urinary Excretion at Day 7 | 1.981 liter per hour (L/h) |
| 10 mg LY2623091 | Pharmacodynamics: Serum to Urine Potassium Area Under the Concentration-Time Curve (AUC) Standardized for Urinary Excretion at Day 7 | 1.788 liter per hour (L/h) |
| 25 mg LY2623091 | Pharmacodynamics: Serum to Urine Potassium Area Under the Concentration-Time Curve (AUC) Standardized for Urinary Excretion at Day 7 | 1.551 liter per hour (L/h) |
| 50 mg Eplerenone | Pharmacodynamics: Serum to Urine Potassium Area Under the Concentration-Time Curve (AUC) Standardized for Urinary Excretion at Day 7 | 1.838 liter per hour (L/h) |
Secondary
Pharmacokinetics LY2623091: Area Under the Concentration-Time Curve (AUC) at Day 6
AUC from time 0, extrapolated to infinity, estimated for LY2623091.
Time frame: Day 6: Predose,1hr, 2hr, 3hr, 4hr, 8hr and 12 hr Postdose
Population: All participants who received at least 1 dose of study drug and for whom the data are considered sufficient and interpretable.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Pharmacokinetics LY2623091: Area Under the Concentration-Time Curve (AUC) at Day 6 | 0.123 microgram*hour per milliliter (µg*h/mL) | Standard Deviation 0.0141 |
| 0.3 mg LY2623091 | Pharmacokinetics LY2623091: Area Under the Concentration-Time Curve (AUC) at Day 6 | 0.444 microgram*hour per milliliter (µg*h/mL) | Standard Deviation 0.0741 |
| 1 mg LY2623091 | Pharmacokinetics LY2623091: Area Under the Concentration-Time Curve (AUC) at Day 6 | 5.50 microgram*hour per milliliter (µg*h/mL) | Standard Deviation 1.08 |
| 10 mg LY2623091 | Pharmacokinetics LY2623091: Area Under the Concentration-Time Curve (AUC) at Day 6 | 13.7 microgram*hour per milliliter (µg*h/mL) | Standard Deviation 2.37 |
Secondary
Pharmacokinetics of LY2623091: Maximal Concentration (Cmax) at Day 6
Cmax estimated for LY2623091.
Time frame: Day 6: Predose,1hr, 2hr, 3hr, 4hr, 8hr and 12 hr Postdose
Population: All participants who received at least 1 dose of study drug and for whom the data are considered sufficient and interpretable.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Pharmacokinetics of LY2623091: Maximal Concentration (Cmax) at Day 6 | 7.57 nanograms per milliliter (ng/mL) | Standard Deviation 0.776 |
| 0.3 mg LY2623091 | Pharmacokinetics of LY2623091: Maximal Concentration (Cmax) at Day 6 | 27.5 nanograms per milliliter (ng/mL) | Standard Deviation 5.19 |
| 1 mg LY2623091 | Pharmacokinetics of LY2623091: Maximal Concentration (Cmax) at Day 6 | 324 nanograms per milliliter (ng/mL) | Standard Deviation 55.2 |
| 10 mg LY2623091 | Pharmacokinetics of LY2623091: Maximal Concentration (Cmax) at Day 6 | 812 nanograms per milliliter (ng/mL) | Standard Deviation 106 |